? Rubius Therapeutics $RUBY has posted some positive ? though preclinical ? study results on its red blood cell tech, saying they were able to track a desired immune response using their drugs.The therapies are designed to increase the flow of T cells to a tumor, mobbing cancer cells in the process.
? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]
? San Diego-based Turning Point Therapeutics has hit the high end of the range it set for their IPO, pricing an upsized set of 9.3 million shares at $18 a pop. They ended up with $166 million raise, which will go a long way to inspiring more industry I… […]
Novo helps birth startup advancing an AstraZeneca castoff with $15M; Japan’s Fuji Pharma wagers $50M on Alvotech’s biosimilars
? With backing from Novo Holdings and a drug from AstraZeneca, Aristea Therapeutics is unveiling a $15 million Series A that will kickstart Phase II studies of its lead program, RIST4721. James Mackay, who used to run AstraZeneca-acquired Ardea Bioscie… […]